

33rd Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting

DELEGATE HANDBOOK



Image supplied by City of Newcastle

22nd – 25th October, 2023

Newcastle City Hall, New South Wales

www.anzbmsconference.org



Gold & Coffee Sponsor



Gold Sponsor



Destination Sponsor



Destination
NSW

Symposium Sponsor



Exhibitors



ANZBMS



bone
health
FOUNDATION



GEDEON RICHTER



CONTENTS

CONTENTS	2
WELCOME FROM THE PRESIDENT	2
SOCIETY SECRETARIATS	3
ANZBMS 2023 COMMITTEE	4
ANZBMS OFFICE BEARERS 2023	4
PAST ANZBMS OFFICE BEARERS 1988-2022	4
SPONSORS & AWARDS OF THE AUSTRALIAN & NEW ZEALAND BONE & MINERAL SOCIETY	5
DELEGATE INFORMATION	11
INVITED PLENARY SPEAKERS	15
INVITED SYMPOSIUM SPEAKERS	15
2023 PROGRAM	16
SUNDAY 22ND OCTOBER 2023	16
MONDAY 23RD OCTOBER 2023	17
TUESDAY 24TH OCTOBER 2023	22
WEDNESDAY 25TH OCTOBER 2023	26
POSTER LISTING	29
PLENARY POSTERS (CONCERT HALL FLOOR)	30
POSTER TOUR 1 - TOP 5 CLINICAL & BASIC SCIENCE POSTERS (CUMMINGS ROOM)	30
ANZBMS POSTER VIEWING - ODD NUMBERS (CUMMINGS ROOM)	31
POSTER TOUR 2 - CHRISTOPHER AND MARGIE NORDIN YOUNG INVESTIGATOR AWARD POSTERS (CUMMINGS ROOM)	32
ANZBMS POSTER VIEWING - EVEN NUMBERS (CUMMINGS ROOM)	33
SPONSOR AND TRADE PARTICIPANTS	35
EXHIBITION FLOOR PLAN – CONCERT HALL FLOOR.....	35
GOLD & COFFEE CART SPONSOR	35
GOLD SPONSOR	35
SYMPOSIUM SPONSOR.....	36
EXHIBITORS	36
ATTENDEES	37
NOTES	40

WELCOME FROM THE PRESIDENT

The President of ANZBMS and the Program and Local Organising Committee Chairs extend the warmest welcome to you for our Annual Scientific Meeting in Newcastle, situated in a beautiful region of New South Wales. Whether you are a young investigator, clinician, basic scientist, allied health professional, or industry representative, there is much on offer for you at this year's meeting.

The Program Organising Committee, co-chaired by Ayse Zengin, Peter Simm and Hong Zhou, have put together an exciting program of cutting-edge science in Bone and Mineral Research and musculoskeletal health that will appeal to clinicians and basic scientists.

Key session themes include:

Ageing successfully

Bone marrow microenvironment

Current therapeutic challenges

Macrophages regulation of skeletal homeostasis

Models of Human Disease

OMICS and bone

Patients, policy and advocacy

Phosphate metabolism and therapeutics

Rare bone diseases

Come along and pick a team at the Great Debate "Animal models are an accurate model of human disease" – sure to spark some controversy. On social, networking and career development, we'll have the renowned Bones and Brews networking event, speed networking, Clinical Cases in Metabolic Bone Diseases dinner, and a career development breakfast "Tackling Academic Promotions and Burnout". Along with the always popular Welcome Function with plenary posters, the Conference Gala Dinner is always a meeting highlight where you can catch up with friends and colleagues, celebrate award recipients, and dance the night away.

We can't wait to see you all and enjoy rekindling our networks and alliances for scientific discourse – the true purpose, of a scientific meeting.

Welcome all.

Mark Forwood

President of ANZBMS

SOCIETY SECRETARIATS

ANZBMS

Ivone Johnson

ijohnson@anzbms.org.au

www.anzbms.org.au

Conference Secretariat – ASN Events

Jim Fawcett

Jim.f@asnevents.net.au

www.asn.events

ANZBMS 2023 COMMITTEE

A/Prof Peter Simm
Royal Children's Hospital Melbourne
 ANZBMS POC Co-Chair

Dr Ayse Zengin
Monash University Australia
 ANZBMS POC Co-Chair

Prof Hong Zhou
University of Sydney
 ANZBMS POC Co Chair

EARLY CAREER COMMITTEE MEMBERS

Dr Bridie Mulholland
Co-Chair and Events
University of Wollongong
 ANZBMS

Dr Hahn Nguyen
Career Dev.
Monash University
 ANZBMS

Dr John Kemp
Past Co-chair & POC
University of Queensland
 ANZBMS

Dr Cass Smith
Co-Chair and Clinical
Edith Cowan University

Dr Jason Talevski
Events (Lead)
Deakin University
 ANZBMS

Dr Amy Harding
Events
Menzies Health Institute
Queensland
 ANZBMS

Dr Jack Dalla-Via
Career Dev. (Lead)
Edith Cowan University
 ANZBMS

Dr Kara Anderson
Comms (Lead)
Deakin University
 ANZBMS

Dr Lena Batoon
Comms
University of QLD
 ANZBMS

Dr Albert Kim
Clinical (Lead)
Westmead Hospital
 ANZBMS

Dr Pamela Rufus-Membrane
Career Dev.
Deakin University
 ANZBMS

Dr Madhuni Herath
Clinical
Hudson Institute of Medical
Research
 ANZBMS

ANZBMS OFFICE BEARERS 2023

ANZBMS President
 ANZBMS President Elect
 ANZBMS Treasurer
 ANZBMS Past President

Prof Mark Forwood
 Prof Mark Cooper
 A/Prof Rachel Davey
 Prof Natalie Sims

ANZBMS Councillors
 Dr Melissa Cantley, A/Prof Cherie Chiang,
 A/Prof Dawn Coates, A/Prof Josh Lewis & Dr Michelle
 McDonald

PAST ANZBMS OFFICE BEARERS 1988-2022

YEAR	PRESIDENT	VICE PRESIDENT PRESIDENT ELECT	SECRETARY	TREASURER	COUNCILLORS
1990 - Steering Group	T.J.Martin		M.Hooper		A.Need, R.Prince, J.Eisman, I.Reid, K.Ibbertson, D.Fraser, P.Sambrook, E.Seeman
1991-93 - Inaugural Council	T.J.Martin		M.Hooper	M.Hooper	J.Eisman, A.Goulding, D.Perry-Keen, J.Wark, A.Need, N.Kent
1993-95	J.Eisman	I.Reid	N.Kent	J.Wark	P.Sambrook, A.Need, R.Prince, D.Perry-Keene, E.Seeman
1995-97	I.Reid	N.Kent	J.Moseley	P.Ebeling	P.Sambrook, A.Need, R.Prince, D.Perry-Keene
1997-99	N.Kent	P.Ebeling	J.Moseley	P.Ebeling	R.Prince, I.Reid, M.Hooper, H.Morris, M.Forwood
1999-01	P.Ebeling	M.Hooper	J.Cornish	M.Forwood	J.Moseley, H.Morris, E.Mackie, M.Zheng

YEAR	PRESIDENT	VICE PRESIDENT PRESIDENT ELECT	SECRETARY	TREASURER	COUNCILLORS
2001-03	M.Hooper	E.Seeman	J.Cornish	M.Forwood	R.Mason, R.Price, D.Findlay, G.Nicholson
2003-05	E.Seeman	J.Cornish	D.Findlay	M.Forwood	R.Mason, R.Price, G.Nicholson, P.Sambrook
2005-07	J. Cornish	P. Sambrook	D. Findlay	R. Price	R. Mason, G. Nicholson, P. Nash, M. Gillespie
2007-09	P. Sambrook	R. Mason	M. Gillespie	R. Price	P. Nash, N. Fazzalari, M. Kotowicz, T. Cundy
2009-11	R. Mason	M. Gillespie	N. Fazzalari	R. Price	P. Sambrook, N. Sims, M. Seibel, G. Thomas, N. Gilchrist
2011-13	M.Gillespie	M. Seibel	G. Atkins	G. Thomas	N. Sims, M. Bolland, C. Inderjeeth, N. Pocock, R. Mason
2013-15	M. Seibel	E. Duncan	G. Atkins	G. Thomas	N. Sims, M. Gillespie, N. Pocock, N. Pavlos, E. Dennison
2015 - 17	E. Duncan	P. Croucher	P. Anderson	N. Pavlos	R. Daley, R Buchbinder, N. Pocock, A. Pettit, E. Dennison
2017 – 19	P.Croucher	N.Sims	P.Anderson	N.Pavlos	A.Pettit, R.Daly, M.Cooper, J.Cornish, M.Forwood, E.Duncan
2019 – 21	N. Sims	M. Forwood	P. Anderson	N. Pavlos	A. Pettit, R. Davey, M. Cooper, J. Cornish, G. Duque, P. Croucher
2021 - 22	M. Forwood	M.Cooper	D.Coates	R. Davey	M. Cantley, C. Chiang, D. Coates, J. Lewis, M. McDonald, N. Sims

SPONSORS & AWARDS OF THE AUSTRALIAN & NEW ZEALAND BONE & MINERAL SOCIETY

ROGER MELICK YOUNG INVESTIGATOR AWARD



This award is presented to commemorate the contribution of Dr Roger Aziz Melick to endocrinology and student education. Roger Melick died in November 1986 after a long battle with cancer. He trained in endocrinology with Fuller Albright, in Boston, and joined The Royal Melbourne Hospital as the third member of the foundation Department of Medicine. He was appointed Dean of the Clinical School in April 1979 and he was forced to retire because of his illness during 1986. Roger Melick was particularly known for his kindness, consideration and empathy for both patients and students. The prize is awarded annually to young members of the Society working towards a higher degree (including FRACP).

1996	Vicky Kartsogiannis	2005	James Doecke	2014	Hua Ying
1997	Linda Crofts	2006	Yosuke Kawasaki		Irina Kulina
1998	Janelle Barry	2007	Stella Foley	2015	Niloufar Ansari
1999	Liza-Jane Raggatt		Garry Williams	2016	Christina Vrahnas
2000	Sandra Iuliano-Burns	2008	Jonathan Gooi	2017	Mahmoud Bakr
	Nathan Pavlos	2009	Nicola Lee	2018	Jun Li
2001	David Good	2010	Irene Zinonos	2019	Amy Harding
2002	Kun Zhu	2011	Chiaming Fan	2020	James Smith
2003	Agatha Labrinidis	2012	Farzin Takyar	2021	Ruby Oberin
	Xiaofang Wang		Audrey Chan	2022	Kaitlyn Flynn
2004	Susan Allison	2013	Asiri Wijenayaka		
	Kirk Ho Man Yip				

CHRISTOPHER AND MARGIE NORDIN YOUNG INVESTIGATOR POSTER AWARD



This Award is named in honour of the outstanding and major clinical investigations into disorders of bone and mineral metabolism made by Professor Christopher Nordin and his contributions to the ANZBMS. Professor B.E Christopher Nordin was a senior specialist at the Institute of Medical and Veterinary Science in Adelaide, and the man credited with drawing the medical community's attention back to the link between calcium deficiency and osteoporosis (brittle bones).

1997	Anne Nelson		Catherine Wang	2015	Dzenita Muratovic – Clinical,
	Hidenori Murata	2006	Andrew Hattam		Scott Youlten – Basic
1998	Marianne Holzherr		Estabelle Ang	2016	Audrey Chan
1999	Tanya Uebergang	2007	Taksum Cheng	2017	Scott Youlten
2000	Josef Kaplan	2008	Hasnawati Saleh	2018	Alexander Rodriguez
2001	Rebecca Jackson	2009	Ee-Cheng Khor	2019	Amy Ribet
2002	Nathan Pavlos	2010	Kylie Alexander	2020	Ruby Oberin
2003	Nicole Walsh	2011	Shek Man Chim	2021	Amy Ribet
	Rouha Granfar	2012	Alvin Ng	2022	Selwin Gabriel Samuel
2004	Laura Gregory		Marie-Luise Wille		
	Mark Bolland	2013	Yu Wen Su		
2005	Mark Bolland	2014	Masato Koike		

CHRISTINE AND T JACK MARTIN RESEARCH TRAVEL GRANT



This grant is offered by the ANZBMS in memory of Christine Martin and to honour the outstanding and major scientific contributions of Professor T Jack Martin to bone and mineral research and his contributions to associates and trainees in teaching, research, and administration.

2002	Catherine Middleton-Hardie	2010	Garry Williams	2019	Sabashini Ramchand
2003	Vicky Kartsogiannis	2011	Julie Quach	2020	*Not Awarded
2004	Kerrie Sanders	2012	Ashika Chhana	2021	*Not Awarded
2005	Susan Allison	2013	Yohann Bala	2022	Ahmed Al Saedi
2006	Mark Forwood	2014	Michelle McDonald		Niloufar Ansari
2007	Brya Matthews	2015	Christina Vrahnas		Martha Blank
2008	Roger Zebaze	2016	Audrey Chan		Pholpat Durongbahn
2009	Bich Tran	2017	Alexander Rodriguez	2023	Ayse Zengin
		2018	Thao Ho-Le		

ANZBMS BONE HEALTH FOUNDATION GRANT



2021	Michelle McDonald, Fran Milat
2022	Nathan Pavlos, Sandra Iuliano

ANZBMS OUTSTANDING ABSTRACT AWARD

The Council of ANZBMS wishes to recognise the high standard of bone and mineral research presented at the Annual Scientific Meeting. The Program Organising Committee will award a prize to the basic and clinical abstracts receiving the highest scores.

2003	Rob Will, Amanda Devine		Brennan, Jasreen Kular,		Natalie Hyde, Michelle
2004	Roger Zebaze		Markus Seibel		McDonald
2004	Christine Rodda	2011	Ian Reid, Asiri Wijenayaka	2017	Victoria D Leitch, Emma M
2005	Markus Seibel, Julian	2012	Ego Seeman, Rachelle		Wade, Michelle M
	Quinn		Johnson		McDonald, Ego Seeman
2006	Yosuke Kawasaki, Julie	2013	Peter Ebeling, Rossana	2018	Ian Reid, Nathan Pavlos
	Kuliwaba, Stella Foley,		Nogueira, Simon	2019	Kai Chen, Robin Daly
	Dana Bliuc, Jonathan Gooi,		Junankar, Narelle	2020	Sandra Iuliano, Peter
	Hugh Zhang		McGregor, Jinwen Tu		Ebeling, Audrey Chan,
2007	Colin Dunstan, Richard	2014	Allison Pettit, Paul		Victoria Leitch, Tsuyoshi
	Prince, Maria Chiu, Natalie		Baldock, Jinwen Tu, Roger		Isojima
	Sims, Paul Baldock, Ian	2015	Zebaze, Kirtan Gandaz	2021	Dana Bliuc, Ryan Chai,
	Parkinson, Hong Zhou		Michelle McDonald,		Alexander Corr, Albert
2008	Robert Kalak, Andrew		Allison Pettit, Audrey	2022	Kim, Alexander Rodriguez
	Grey		Chan, Le Phong Thao Ho,		Charles Inderjeeth,
2009	Vicky Kartsogiannis,		Ayano Nakayama		Michael J Rogers,
	Nguyen Nguyen	2016	Nicola Lee, Steven		Minghao Zheng, Brya
2010	Markus Seibel, Emma		Watson, Emma Walker		Matthews, John Eisman
	Walker, Iris Wong, Sarah				

ANZBMS CLINICAL RESEARCH EXCELLENCE AWARD

This award is offered to recognise and support clinicians in or within 10 years of postgraduate training who are contributing to clinical research in the field of bone-related disorder.

2012	Belal Khan	2013	Syndia Lazarus		
2014	Masakazu Kogawa	2016	Thack Tran	2018	Jasna Aleksova
2015	Hanh Nguyen	2017	Weiwien Chen	2019	Alexander Rodriguez

ANZBMS KAYE IBBERTSON AWARD FOR BONE AND MINERAL MEDICINE



This Award is named in honour of the outstanding career and major investigations into skeletal disorders made by Professor Kaye Ibbertson, and his contributions to the ANZBMS.

2005	Roger Zebaze	2015	Joshua Lewis
2006	Julie Pasco		Rachelle Johnson
2007	Tania Winzenberg	2016	Michelle McDonald
2008	Paul Baldock	2017	Feitong Wu
2009	Mark Bolland	2018	Dawn Aitken
2010	Kun Zhu	2019	Fran Milat
2011	Susannah O'Sullivan	2020	David Scott
2012	Emma Duncan	2021	John Kemp
2013	Tara Brennan-Speranza	2022	Natalie Wee
2014	Nicole Yu		

SOL POSEN RESEARCH AWARD



This Award is named in honour of Professor Sol Posen who was one of the pioneers in the field of bone and mineral endocrinology in this country. Sol Posen's contributions span the range from basic biochemistry – his citation classic in Clinical Chemistry described the first means of distinguishing alkaline phosphatase of bone origin – to clinical studies in metabolic bone disease, including Paget's disease, osteoporosis, hyperparathyroidism and tumour-induced osteomalacia. He attended meetings and journal clubs, where his presence was marked, as ever, by his propensity to ask incisive questions.

2006	Nathan Pavlos	2012	Julie Quach	2018	Nicola Lee
2007	Aaron McDonald	2013	Farzin M Takyar	2019	Kai Chen
2008	Haotian Feng	2014	Heath McGowan	2020	Jungie Gao
2009	Ming-Kang Chang	2015	Dana Bliuc	2021	Niloufar Ansari
2010	Tak Sum Cheng	2016	Paul Lee	2022	Kai Chen
2011	Kylie Alexander	2017	Thao P. Ho-Le		

PHILIP SAMBROOK AWARD



The Professor Philip Sambrook Award is presented annually to an outstanding early career researcher to honour the major clinical and scientific contributions by Professor Philip Sambrook to the field of rheumatology and osteoporosis. Successful applicants must be passionate about bone research, results driven and committed to giving back to the community.

2012	Gustavo Duque	2018	Feitong Wu
2013	Emma Duncan	2019	Sabashini Ramchand
2014	Kirtan Ganda	2020	*Not Awarded
2015	Sharon Brennan-Olsen	2021	*Not Awarded
2016	Jinwen Tu	2022	Natalie Hyde
2017	Jansa Aleksova		

ANZBMS INTERNATIONAL TRAVEL AWARD

This award is offered by the ANZBMS to support travel to attend the IBMS Herbert Fleisch Workshop. The objective of this workshop is to provide a Gordon-conference style forum for students, post-docs and early stage principal investigators to present work in progress, discuss thoroughly and network with peers, and get constructive feedback from experienced senior scientists.

2014	Tara Brennan-Speranza, Ashika Channa, Christina, Vrahnas	2015	Campbell Macgregor, Megan Thomas, Scott Youlten	2022	Lena Batoon Ye Cao Annohya Gandham
		2018	Babtunde Ayodele, Dzenita Muratovic		

ANZBMS CAREER ACHIEVEMENT AWARD

This esteem award recognises outstanding and major scientific or clinical contributions, and excellence in teaching and service to and within the bone and mineral field. The award will be widely publicised and presented annually during the society's Annual Scientific Meeting. The awardee will receive free registration to the Annual Scientific Meeting and invitations to the annual and the president's dinner the year the award is received.

2014	Jillian Cornish, Ego Seeman	2018	John Eisman	2022	Rebecca Mason
2015	Howard Morris	2019	Ian Reid		
2016	Jack Martin	2021	David Findlay		

ANZBMS GAP FELLOWSHIP

In recent years, funding for mid-career researchers has become increasingly difficult to obtain, jeopardising the future career of many of our colleagues in bone and mineral research. The ANZBMS has therefore created a new Fellowship Award with the intention to bridge shortfalls in salary funding for outstanding mid-career scientists.

2016	Allison Pettit	2017	Nicki Lee Rachel Davey	2018	Dana Bliuc
------	----------------	------	---------------------------	------	------------

ANZBMS HIGHEST RATED STUDENT ABSTRACT AWARD

The prize, of a single free registration, will be awarded to the student first author of the abstract that receives the highest score from the scoring committee.

2017	Junjie Gao	2019	Kotaro Tanimoto	2021	Shoichiro Tani
2018	Marija Simic	2020	Lena Batoon	2022	Tian Nie

ANZBMS LIFE MEMBERS

Professor Henry Kaye Ibbertson (deceased)	Dr Donald Gutteridge	Professor Jillian Cornish
Associate Professor Jane Moseley	Dr Ailsa Goulding	Professor Rebecca Mason
Professor B.E.C Nordin (deceased)	Associate Professor Michael Hooper	Professor Ian Reid
Dr Solomon Posen (deceased)	Professor John Elsman	Professor David Findlay
Professor Thomas J. Martin	Professor Ego Seeman	

BRIDGING OVERSEAS NETWORKING AND EXCHANGE (B.O.N.E) PROGRAM

The Bridging Overseas Networking and Exchange (B.O.N.E) Program is an ANZBMS Early Career Investigator Committee (ECIC) initiative, established in 2018, to address the limited opportunity and funds for invited presentations for early career investigators (ECI) in the musculoskeletal field. This program will boost ECIs track records, increase their exposure, provide travel support, and facilitate international networking and collaboration – together enabling more competitive track records for future funding opportunities.

2016	Allison Pettit	2019	Michelle McDonald	2022	Timo Damm, Monika Frysz
2017	Nicki Lee, Rachel Davey	2020	Kylie Alexander		
2018	Dana Bliuc				

CLINICAL CASES IN METABOLIC BONE DISEASE SEMINAR AWARD

The Clinical Cases in Metabolic Bone Disease Seminar was established in 2018 to encourage clinical interest in metabolic bone research in junior clinicians. This seminar provides an opportunity for physician trainees to present their case and literature review to a national scientific audience. It is anticipated that each case will spark lively discussion regarding complex areas of metabolic bone disease, engaging both clinicians and scientists. The clinical cases session aims to foster interest in the bone field amongst advanced trainees and senior clinicians and hopes to engage them into the wider clinician-researcher network.

2018	Kate Haigh Alicia Jones	2019	Genevieve Calder	2022	Lucy Collins
------	----------------------------	------	------------------	------	--------------



EVENTITY® works differently* to treat osteoporosis

*EVENTITY builds bone rapidly by simultaneously increasing bone formation and decreasing bone resorption with 12 monthly doses in patients who need it the most¹



PBS Information: Authority Required as treatment for severe established osteoporosis. Criteria Apply. Refer to PBS Schedule for full information.

Refer to full Product Information before prescribing – available from Amgen Australia Ph: 1800 803 638 or at www.amgen.com.au/Eventity.PI

For more information on EVENTITY®, or to report an adverse event or product complaint involving EVENTITY®, please contact Amgen Medical Information on 1800 803 638 or visit www.amgenmedinfo.com.au

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.


EVENTITY MINIMUM PRODUCT INFORMATION. INDICATIONS: Treatment of osteoporosis in postmenopausal women at high risk of fracture. Treatment to increase bone mass in men with osteoporosis at high risk of fracture. **CONTRAINDICATIONS:** Uncorrected hypocalcaemia. Hypersensitivity to romosozumab, CHO-derived proteins or any component. **PRECAUTIONS:** Correct hypocalcaemia prior to initiating therapy. Monitor patients for signs and symptoms. Adequately supplement intake of calcium and vitamin D. Initiate appropriate therapy and discontinue use if anaphylactic or other clinically significant allergic reaction occurs. Consider the benefit-risk in patients at increased risk for myocardial infarction or stroke. Instruct patients to watch for symptoms of myocardial infarction and stroke and to seek prompt medical attention if symptoms occur. Assess cardiovascular risk factors prior to treatment. A patient's suitability for treatment should be based on individual benefit-risk assessment. Consider relative benefits and risks of treatment in patients at high cardiovascular risk. Treatment should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Discontinue use if myocardial infarction or stroke occurs during therapy. Evaluate patients for risk factors for osteonecrosis of the jaw (ONJ); use with caution in these patients. Consider discontinuation if osteonecrosis of the jaw occurs. Rare reports of atypical femoral fractures. **ADVERSE EFFECTS:** Common: nasopharyngitis, arthralgia, back pain, pain in extremity, fall, headache, hypertension, viral upper respiratory tract infection, osteoarthritis, influenza, musculoskeletal pain, upper respiratory tract infection, muscle spasms, dizziness, constipation, cough, urinary tract infection, myalgia, diarrhoea, confusion, gastritis, upper abdominal pain, spinal osteoarthritis, bronchitis, peripheral oedema, asthenia, dyslipidaemia, neck pain, cataract, paraesthesia. **DOSAGE AND ADMINISTRATION:** Subcutaneous injection of 210 mg, once every month for 12 doses. To administer 210 mg, give two subcutaneous injections. Ensure adequate intake of calcium and vitamin D. After completing therapy, transition to antiresorptive osteoporosis therapy. No dose adjustment required in the elderly or in renal impairment. **PRESENTATION:** Pre-filled syringe, supplied as a 2-pack. Refer to full Product Information before prescribing – available from Amgen Australia Ph: 1800 803 638 or at www.amgen.com.au/Eventity.PI. **Reference:** 1. EVENTITY® (romosozumab) Approved Product Information. Available at: www.amgen.com.au/Eventity.PI

DELEGATE INFORMATION


VENUE

Newcastle City Hall
290 King Street,
Newcastle, NSW 2300
Phone: +61 2 4974 2166


GROUND FLOOR



FIRST FLOOR



UPPER FLOOR



THE REGISTRATION DESK

The registration desk is located in the Concert Hall Foyer, located on the first floor of the Newcastle City Hall. Any enquiries can be directed to ASN staff located at the registration desk except those regarding accommodation which should be dealt directly with your hotel.

The registration desk office hours are:

Sunday 22 nd October	2:30PM – 6:30PM
Monday 23 rd October	6:30AM – 4:00PM
Tuesday 24 th October	6:30AM – 6:00PM
Wednesday 25 th October	8:30AM – 4:00PM

LOADING YOUR ORAL PRESENTATION AT THE CONFERENCE

Oral presenters should bring their talk on a USB, saved in a format for display on a PC within the Concert Hall (i.e. PowerPoint). You will need to load your presentation directly into the room in which you are presenting. A technician will be on hand to assist with any transfer / loading issues and to help you check your presentation. Please note there are no Macintosh computers in the presentation room – please format your USB drives appropriately (FAT32).

REGISTRATION

Conference delegates receive the following services as part of their registration:

- Access to the sessions of your choice
- Conference book
- Use of the Conference App
- Morning and/or afternoon tea for the days of nominated attendance
- Lunches on the days of nominated attendance
- Welcome Function (Sunday 22nd October)

NAME TAGS

Delegates are required to wear their name tags to all scientific and catered sessions. Delegates should note that within their name tag pouch will be the specific function tickets they have purchased.

POSTER VIEWING

Delegates with posters can find the correct position for their poster by locating the appropriate abstract number on the display panels. The Plenary posters are displayed on the Concert Hall Floor, located on the first floor. Poster Tours (and sessions) will be located in the Cummins Room located on the first floor. Use the program reference (or ANZBMS smart phone APP) to identify your abstract number and poster position. Presenters should stand next to their poster during allocated poster sessions. **All posters** can be mounted on **Sunday afternoon** and must be removed by **lunch on Wednesday**.

ANZBMS POSTER TOURS & VIEWING SESSIONS

ANZBMS Plenary Poster Session – 6:00PM – 7:30PM, Sunday 22nd October (Concert Hall Floor)

ANZBMS Poster Tour 1 (Top 5 Clinical & Basic Science Posters) – 4:00PM – 5:30PM, Monday 23rd October (Cummings Room)

ANZBMS Poster viewing - Odd numbers – 4:00PM – 5:30PM, Monday 23rd October (Cummings Room)

ANZBMS Poster Tour 2 - Christopher & Margie Nordin Posters – 10:00AM – 11:30AM, Tuesday 24th October (Cummings Room)

ANZBMS Poster viewing - Even numbers – 10:00AM – 11:30AM, Tuesday 24th October (Cummings Room)

RECORDING & STREAMING OF SESSIONS AT ANZBMS 2023

All sessions within the Concert Hall will be recorded and live streamed at the conference. If you do not wish to have your presentation recorded, please advise ASN Staff at the registration desk. Details on accessing the live stream and recordings have been previously sent to your email.

LECTURE ROOMS

All mainstream lectures for the meeting will run within the Concert Hall at the Newcastle City Hall. All lunchtime & breakfast symposiums will run within the Hunter Room.

PARENTS ROOM

The conference livestream will be broadcast into the Hunter Room at ANZBMS for those with infants attending the meeting.

SOCIAL FUNCTIONS

Welcome Function

Date: Sunday 22nd October 2023

Time: 6:00PM – 7:30PM

Price: Complimentary with Full Conference Registration

Location: Concert Hall Floor, Newcastle City Hall

Additional ticket: \$65.00

**Additional tickets for partners can be purchased in advance or at the registration desk.*

ECIC - 'Bones & Brews' Networking Dinner

Date: Sunday 22nd October 2023

Time: 7:30PM – 10:00PM

Location: Foghorn Brewery

Cost: \$40.00

Student/ECR cost: \$25.00

**This is a ticketed function; tickets can be purchased in advance or at the registration desk.*

ECIC Career Development Breakfast

Date: Monday 23rd October 2023

Time: 7:30AM – 9:00AM

Price: Free to all attendees

Location: Hunter Room. Breakfast provided.

Clinical Cases in Metabolic Diseases Seminar

Date: Monday 23rd October 2023

Time: 7:30PM – 8:00PM

Price: \$35 (Trainee or Student), \$50 (others)

Location: Hunter Room. Dinner and drinks provided

ANZBMS Conference Dinner

Date: Tuesday 24th October 2023

Time: 7:00PM - Late

Price: \$60 (Student/ECR), \$100 (Other)

This is a ticketed function; tickets can be purchased in advance or at the registration desk. Buses will transport people to the venue and will depart the Newcastle City Hall at **7:00pm and will be available to pick up guests from Noah's back to the Newcastle City Hall at **9:30pm**, **10:30pm** and **11:30pm**.*

Supported by 

DIETARY REQUIREMENTS

If you requested a special meal, please make yourself known to the venue staff and advise your name and special request.

SMOKING

Smoking is not permitted in the venue.

MOBILE PHONES

Please ensure your mobile phone is turned off or on silent during any session you attend.

INSURANCE

The hosts and organisers are not responsible for personal accidents, any travel costs, or the loss of private property and will not be liable for any claims. Delegates requiring insurance should make their own arrangements.

DISCLAIMER

The hosts, organisers and participating societies are not responsible for, or represented by, the opinions expressed by participants in either the sessions or their written abstracts.

WI-FI INTERNET

The Newcastle City Hall provides complimentary Wi-Fi and signage will be placed around the venue and at the registration desk for access.

CONFERENCE APP

The App is displayed in a simple and easy to read format on your phone, iPad, or even your computer. To get the 'App', please open the following link in your internet browser on your phone, iPad or laptop: <http://anzbms-2023.m.asnevents.com.au/>

Alternatively, scan the QR code below.



You will be prompted to add an icon onto your device home screen. The Smartphone/Mobile Device 'App' will allow you to:

- View the full conference program
- View all abstracts for the conference
- View the author listing
- Save your favourite sessions and plan your day
- Take notes which will then be saved and downloaded from your registration profile.
- To use most of these functions, you will be prompted to 'log in' each day.

INVITED PLENARY SPEAKERS

Dr Lama Alabdulaaly

Harvard School of Dental Medicine, Boston, USA

Professor Yumie Rhee

Yonsei University College of Medicine, Seoul, South Korea

Dr Laura Calvi

University of Rochester, New York State, USA

Dr Michaela Tencerova

*Institute of Physiology of the Czech Academy of Sciences,
Prague, Czech Republic*

INVITED SYMPOSIUM SPEAKERS

Mrs Solange Bernardo

*Australian Institute for Musculoskeletal
Science
Melbourne, Australia*

Dr Ryan Chai

*Garvan Institute of Medical Research
NSW, Australia*

Dr Kai Chen

*The University of Western Australia
Perth, Australia*

Prof Roderick Clifton-Bligh

*The University of Sydney
NSW, Australia*

Professor Jill Cornish

*University of Auckland
Auckland, New Zealand*

Natalie Hyde

*Geelong Osteoporosis Study
Geelong, Australia*

Professor Susan Kurrle AO

*Hornsby Ku-ring-gai Hospital
Sydney, Australia*

Dr Syndia Lazarus

*Department of Endocrinology
QLD, Australia*

Greg Lyubomirsky, CEO

*Health Bones Australia
NSW, Australia*

A/Prof Nathan Pavlos

*The University of Western Australia
WA, Australia*

Associate Professor David Scott

*Deakin University
Melbourne, Australia*

Professor Natalie Sims

*The University of Melbourne
Melbourne, Australia*

Dr Joel Vanderniet

*The Children's Hospital Westmead
NSW, Australia*

2023 PROGRAM

SUNDAY 22ND OCTOBER 2023

Tastes of the Hunter Valley Excursion

8:30AM - 2:00PM

Meet outside Newcastle City Hall at 8:15AM ready to depart at 8:30AM sharp!

Hunter Valley

ANZBMS Presidents Cocktail Lunch

12:30PM – 1:30PM

By invitation of ANZBMS President only.

Crystalbrook Kingsley

Registration Open

2:30PM - 6:30PM

Concert Hall Foyer

ANZBMS Council Meeting

1:45PM – 3:30PM

By invitation of ANZBMS Council only.

Mulumbinba Room

Science at Speed Networking Session Hosted by the ANZBMS ECIC

4:00PM - 5:30PM

Hunter Room

Welcome Function + Plenary Posters

6:00PM - 7:30PM

Concert Hall Floor

Bones and Brews

7:30PM - 10:00PM

Foghorn Brewery

MONDAY 23RD OCTOBER 2023

Registration Open

6:30AM - 4:00PM

Concert Hall Foyer

ECIC Career Development Breakfast - Tackling Academic Promotions and Burnout

7:00AM - 8:30AM

Hunter Room

Part One: Tackling Academic Promotions

Dr Bridie Mulholland – Early career perspective

Dr Marc Sim – Moving from level B to C

Prof Mark Forwood – Perspectives from a promotion assessment committee

Part Two: Tackling Burnout

Professor Yumie Rhee

Ageing Successfully Symposium

8:30AM - 9:00AM

Concert Hall Auditorium

Chairs: Mark Cooper & Ayse Zengin

8:30 AM

Susan Kurrle

Successful Ageing Symposium *abs# 1*

ANZBMS Outstanding Oral Abstracts

9:00AM - 10:00AM

Concert Hall Auditorium

Chairs: Mark Cooper & Ayse Zengin

9:00 AM

Varun S Venkatesh

Identifying the proteins secreted by bone marrow mesenchymal precursor cells responsible for negatively regulating fat mass in male mice. *abs# 2*

9:15 AM

Benjamin H Mullin

Co-localisation between genome-wide association and gene expression data identifies *ATP6V1A* as a potential regulator of bone mineral density that acts through osteoclasts *abs# 3*

9:30 AM

Sandra Iuliano

Reducing hip and non-vertebral fractures in institutionalised older adults by restoring inadequate intakes of protein and calcium is cost-saving *abs# 4*

9:45 AM

Charles Inderjeeth

Acetylcholinesterase inhibitors reduce fracture and mortality risk in older patients with dementia syndromes *abs# 5*

Morning Tea

10:00AM - 10:45AM

Concert Hall Floor

ANZBMS Outstanding Student Oral

10:45AM - 10:58AM

Concert Hall Auditorium

Chairs: Jillian Cornish & Peter Wong

10:45 AM

Kavindi Weerasinghe

Effects of antipsychotics on embryonic bone development *abs# 6*

ANZBMS Roger Melick Young Investigator Award Symposium

10:58AM - 1:00PM

Concert Hall Auditorium

Chairs: Jillian Cornish & Peter Wong

10:58 AM

Natalie YY Koh

Lysosomal proteins Legumain and Cathepsin B expressed within osteocytes cleave Collagen Type I *abs# 7*

11:11 AM

Abadi Kahsu Gebre

Elevated High-sensitivity Cardiac Troponin I is Associated with Fall and Fracture-Related Hospitalizations in Older Women *abs# 8*

11:24 AM

Christal K-Y Au-Yeung

Engineering cell and animal models of dominant-negative osteogenesis imperfecta using CRISPR *abs# 9*

11:37 AM

Prageeth Gamage

A network meta-analysis: Association between osteoporotic drug therapies and cardiovascular diseases, including atrial fibrillation. *abs# 10*

11:50 AM

Jacob W Harland

Bone mineral density and trabecular bone score values in novel subgroups of adult-onset diabetes *abs# 11*

12:03 PM

Huy G Nguyen

Development of Artificial Intelligence System for Predicting Areal Bone Mineral Density from Plain Radiographs *abs# 12*

12:16 PM

Behnaz Azimi Manavi

Schizophrenia and bone fragility: A systematic review and meta-analyses *abs# 13*

12:29 PM

Shejil Kumar

The Tyr Phenomenon: A Hypocalcaemic Response in High-Volume Treatment Responders to ¹⁷⁷Lu-PSMA Therapy *abs# 14*

12:42 PM

Mary Louise Fac

In elderly women, bone deposited in regions of high cortical porosity is less mineralised and has a higher carbonate content than that of younger women *abs# 15*

Lunch

1:00PM - 2:00PM

Concert Hall Floor

Amgen Lunchtime Symposium - Tailoring treatments according to fracture risk

1:00PM - 2:00PM

Chair: Jeffrey Hassall

Hunter Room

Symposium supported by



1:00 PM

Peter Ebeling

Osteoanabolic therapy

Optimal sequencing of osteoporosis therapies

Role of Macrophages in Bone Homeostasis Symposium

2:00PM - 2:30PM

Chairs: Allison Pettit & Christian Girgis

Concert Hall Auditorium

2:00 PM

Laura Calvi

Reciprocal interactions of bone marrow macrophages and mesenchymal stromal cells impact skeletal homeostasis *abs# 16*

ANZBMS Selected Orals

2:30PM - 3:30PM

Chairs: Allison Pettit & Christian Girgis

Concert Hall Auditorium

2:30 PM

Allison R Pettit

Delayed skeletal development in CSF1R-deficient rats highlights independent contributions of osteal macrophages and osteoclasts to postnatal bone development *abs# 17*

2:42 PM

Michael Thompson

Nonmelanoma skin cancer is associated with fewer incident fractures, more vitamin D sufficiency, greater BMD and improved bone microarchitecture in older adults *abs# 18*

2:54 PM

Sheng Yin

Bacterial heat shock protein: A new crosstalk between T lymphocyte and macrophage via JAK2/STAT1 pathway in chronic osteomyelitis *abs# 19*

3:06 PM

Kara B Anderson

Cardiovascular risk factors and bone mineral density: Data from the Geelong Osteoporosis Study *abs# 20*

3:18 PM

Allison Pettit

Macrophage barnacles muddy the waters of single cell precision profiling of bone and bone marrow cell populations. *abs# 21*

Afternoon Tea

3:30PM - 4:00PM

Concert Hall Floor

ANZBMS Poster tour 1 (Top 5 Clinical & Basic Science Posters)

4:00PM - 5:30PM

Facilitators: Itamar Levinger & Cassandra Smith

Cummings Room (Poster Hall)

ANZBMS Poster viewing - Odd Numbers

4:00PM - 5:30PM

Cummings Room (Poster Hall)

ECIC Clinical Cases in Metabolic Bone Disease Seminar

5:30PM - 8:00PM

Hunter Room

Chairs: Lucy Collins & Shejil Kumar

5:30 PM

Yeung-Ae Park

FGF23-mediated hypophosphataemic osteomalacia with low bone turnover *abs# 22*

5:53 PM

Jeremy A Knott

Diagnostic challenges in a case of refractory severe hypercalcemia: case report *abs# 23*

6:16 PM

Amanda Ji

Polyostotic fibrous dysplasia: will denosumab reduce his bone pain? *abs# 24*

6:39 PM

Mike Lin

Persistent hyperparathyroidism in pregnant women with a prior renal transplant: challenges and treatment strategies. abs# 25

7:02 PM

Evelyn Hao

Severe osteoporosis secondary to systemic mastocytosis exacerbated by pregnancy and breastfeeding *abs# 26*

Seminar supported by  **KYOWA KIRIN**

MINIMUM PRODUCT INFORMATION CRYSVITA® (burosumab) solution for injection

THERAPEUTIC INDICATION: CRYSVITA® (burosumab) is indicated for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older.

DOSE AND ADMINISTRATION: The recommended starting dose regimen for paediatrics (children 1-11yrs and adolescents 12-17yrs) is 0.8 mg/kg of body weight, rounded to the nearest 10 mg, every 2 weeks, up to a maximum dose of 90 mg. The recommended dose regimen in adults (18yrs and older) is 1 mg/kg of body weight, rounded to the nearest 10 mg up to a maximum dose of 90 mg, administered every 4 weeks. Treatment should be initiated and monitored by specialist medical practitioners experienced in the management of patients with metabolic bone disease. Fasting serum phosphate concentration should be below the reference range for age prior to initiation of treatment. CRYSVITA® is administered by subcutaneous injection and should be administered by a healthcare provider. The maximum volume of CRYSVITA® per injection site is 1.5 mL. If multiple injections are required, administer at different injection sites.

CONTRAINDICATIONS: Hypersensitivity to CRYSVITA® or to any of the excipients. Concurrent administration with oral phosphate and / or active vitamin D analogues. Serum phosphate level within or above the normal range for age at initiation of treatment. Severe renal impairment or end stage renal disease.

PRECAUTIONS: Discontinue oral phosphate and active vitamin D analogues at least 1 week prior to initiating CRYSVITA® treatment. Monitor for signs and symptoms of nephrocalcinosis, hyperphosphatemia, ectopic mineralisation, and serious hypersensitivity reactions. Administration should be interrupted in any patient experiencing severe injection site reactions. Discontinue if serious hypersensitivity reaction occurs. Monitoring for signs and symptoms of nephrocalcinosis due to ectopic mineralisation, e.g. by renal ultrasonography, is recommended at the start of treatment and every 6 months for the first 12 months

of treatment, and annually thereafter. Monitoring of urine calcium and phosphate is suggested every 3 months. Monitoring of plasma alkaline phosphatase, calcium, parathyroid hormone (PTH) and creatinine is recommended every 6 months (every 3 months for children 1 - 2 years) or as indicated. **INTERACTIONS:** Concurrent administration of CRYSVITA® with oral phosphate and active vitamin D analogues is contraindicated as it may cause an increased risk of hyperphosphatemia and hypercalcaemia. Caution should be exercised when combining CRYSVITA® with calcimimetic medicinal products. **ADVERSE EFFECTS:** Very common adverse reactions (>10%) reported in paediatric patients (≥1-17yrs) during clinical trials who had received at least 1 dose of CRYSVITA® were: injection site reactions, cough, headache, pyrexia, pain in extremity, vomiting, tooth abscess, vitamin D decreased, diarrhoea, rash, nausea, constipation, dental caries and myalgia. Common adverse reactions (≤10%) reported in paediatric patients ≥1 year of age during clinical trials who had received at least 1 dose of CRYSVITA® were: dizziness and blood phosphorus increased. Very common adverse reactions (>10%) reported in adult patients (≥18yrs) who had received at least 1 dose of CRYSVITA® during clinical trials were: back pain, headache, tooth infection, restless legs syndrome, muscle spasms, vitamin D decrease and dizziness. Common adverse reactions (≤10%) reported in adult patients who had received at least 1 dose of CRYSVITA® during clinical trials were: constipation and blood phosphorus increased. Content based on full CRYSVITA® Product Information. Date Approved: 10 Sept 2021.

Please review full Product Information before prescribing. Product Information is available at: https://www.kyowakirin.com/australia/our_medicines/doc/crysvita_product_information_leaflet.pdf

PBS INFORMATION: This product is listed on the PBS as a Section 100 item.
Refer to PBS Schedule for full authority information.



CRYSVITA[®]

(burosumab)

A fully human monoclonal antibody for XLH^{*} treatment¹


CRYSVITA[®] restores phosphate homeostasis^{2,3}

In Children

Compared to conventional therapy, CRYSVITA[®]:



Significantly improved rickets healing and reduced severity²



Significantly improved growth and mobility outcomes²



Significantly improved biochemical markers of phosphate regulation and bone health²

In Adults

Compared to baseline, CRYSVITA[®]:



Improved fracture and pseudofracture healing⁵



Significantly improved physical function and mobility whilst reducing stiffness and pain at its worst⁵



Improved quality of life^{3,4}

Adverse events were generally mild or moderate in severity^{2,3}
No adverse drug reactions led to treatment discontinuation^{2,3}

PBS INFORMATION: This product is listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority information.

Visit us at ANZBMS booth #1 for further information.

Please review full [Product Information](#) before prescribing. Minimum Product information is available in this booklet. CRYSVITA[®] (burosumab) is indicated for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older.¹

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems. Adverse events can be reported at pv.kkau.2r@kyowakirin.com * XLH: X-Linked Hypophosphataemia

References: **1.** Australian Product Information for Crysivita[®] (burosumab) approved Sep 2021. Available at: https://www.kyowakirin.com/australia/our_medicines/doc/crysvita_product_information_leaflet.pdf. Last accessed June 2022. **2.** Imel EA et al. Lancet 2019;393:2416-2427 **3.** Portale AA, et al. Calcif Tissue Int. 2019;105:271-84 **4.** Briot K, et al. RMD Open 2021;7:e001714. doi:10.1136/rmdopen-2021-001714

TUESDAY 24TH OCTOBER 2023

Registration Open

6:30AM - 6:00PM

Concert Hall Foyer

Alexion Breakfast Symposium - Shining a spotlight on hypophosphatasia (HPP) in children and adults

7:00AM - 8:30AM

Chair: Rebecca Vass

Hunter Room

7:00 AM

Peter Ebeling & Craig Munns

A presentation on diagnosing and differentiating HPP, the importance of real-world practice and data with local clinical cases demonstrating the journey and daily life of paediatric-onset HPP patients.

Topics include:

- HPP diagnosis, manifestations and treatment
- Real world practice, data and registries with clinical cases

Symposium supported by



Denosumab Discontinuation in Postmenopausal Osteoporosis Symposium

8:30AM - 9:00AM

Chairs: Peter Ebeling & Hong Zhou

Concert Hall Auditorium

8:30 AM

Yumie Rhee

Food for thought on the therapeutic regimen after stopping denosumab in postmenopausal women *abs# 27*

Christopher and Margie Nordin Young Investigator Award Symposium (Mini Orals)

9:00AM - 10:00AM

Concert Hall Auditorium

9:00 AM

Jonathan Phuong

An implementation science approach to community pharmacy osteoporosis screening *abs# 28*

9:06 AM

Krisel De Dios

Rate of bone loss is associated with fracture risk: The Study of Osteoporotic Fractures *abs# 29*

9:12 AM

Micaela Quinn

Skeletal effects of neratinib treatment and *Blautia luti* supplementation in tibial trabecular bone of albino Wistar rats *abs# 30*

9:18 AM

Mike Lin

Severe Low Bone Mineral Density is Common in Patients with Beta Thalassaemia Major: A Single Centre Experience *abs# 31*

9:24 AM

Pholpat Durongbhan

Quantification of abnormal cortical bone surface remodelling in preclinical models of arthritis *abs# 32*

- 9:30 AM **Khuong-Duy Hoang**
Association between knee osteoarthritis and volumetric bone mineral density *abs# 33*
- 9:36 AM **Mia Percival**
Gestational vitamin D and offspring fracture risk: Do associations persist into mid adolescence? *abs# 34*
- 9:42 AM **Behnaz Azimi Manavi**
Antipsychotic medication use and fracture: a case-control study *abs# 35*
- 9:48 AM **Ngoc Huynh**
Estimating “Skeletal Age” by Bone Loss in Elderly Men and Women *abs# 36*
- 9:54 AM **Lucy Collins**
Does long-term antiresorptive administration lead to atypical fractures at other skeletal sites excluded from the ASBMR atypical femur fracture (AFF) case definition? A systematic review *abs# 37*

Morning Tea

10:00AM - 11:00AM Concert Hall Floor

ANZBMS Poster Tour 2 - Christopher & Margie Nordin Posters

10:00AM - 11:30AM Cummings Room (Poster Hall)
Chairs: Joshua Lewis & Rebecca Mason

ANZBMS Poster viewing - Even numbers

10:00AM - 11:30AM Cummings Room (Poster Hall)

OMICS Symposium - Single cell transcriptomics in bone

11:30AM - 12:30PM Concert Hall Auditorium
Chairs: John Kemp & Michelle McDonald

11:30 AM **Benjamin Parker**
In vivo phosphoproteomics and functional genomics of insulin signalling in bone *abs# 38*

12:00 PM **Ryan C Chai**
Single-cell RNA sequencing: unravelling the bone one cell at a time *abs# 39*

ANZBMS Selected Orals

12:30PM - 1:30PM Concert Hall Auditorium
Chairs: John Kemp & Michelle McDonald

12:30 PM **Marc Sim**
Frailty is associated with greater long-term risk for fall and fracture-related hospitalisations as well as mortality in community-dwelling older Australian women *abs# 40*

- 12:42 PM **Michelle McDonald**
RANKL inhibition creates a pro-osteoclastic environment, leading to an overshoot in serum TRAP and accelerated bone resorption following treatment withdrawal. *abs# 41*
- 12:54 PM **Belinda Beck**
Preventing Bone and Muscle Injury and Reducing Costs in Australian Army Recruit Training with Bone-Targeted Pre-Conditioning: The PREFIT Study *abs# 42*
- 1:06 PM **Eugenie Macfarlane**
Deletion of the chondrocyte glucocorticoid receptor attenuates cartilage degradation through suppression of early synovial activation in murine posttraumatic osteoarthritis *abs# 43*
- 1:18 PM **Jakub Mesinovic**
Effects of high-intensity resistance and impact exercise on changes in body composition and metabolic and musculoskeletal health during weight loss in older adults with obesity: A pilot randomised controlled trial *abs# 44*


Lunch

1:30PM - 2:30PM Concert Hall Floor

Kyowa Kirin Lunchtime Symposium - The Australian Crystiva XLH Experience - 12 months of PBS access.

1:30PM - 2:30PM Hunter Room

- 1:30 PM **Peter Ebeling**
Introduction & Welcome to Country
- 1:40 PM **Roderick Clifton-Bligh**
Long-term efficacy and safety of CRV in adult XLH patients
- 1:50 PM **Roderick Clifton-Bligh & Margaret Zacharin**
Forum & Q&A - real world use and practical considerations of CRV in Australia, featuring case studies from each speaker

Symposium supported by  **KYOWA KIRIN**

Rare Bone Diseases Symposium

2:30PM - 3:30PM Concert Hall Auditorium

Chairs: Peter J Simm & Tania Crotti

- 2:30 PM **Joel A Vanderniet**
Use of denosumab in non-osteoporotic conditions including bone tumours and paediatric use *abs# 45*

- 3:00 PM **Syndia Lazarus**
Hypophosphatasia in the age of miracles *abs# 46*

ANZBMS Selected Orals

3:30PM - 4:30PM Concert Hall Auditorium

Chairs: Peter J Simm & Tania Crotti

- 3:30 PM **Mícheál Ó Breasail**
Impact of HIV on radial bone density, geometry, and strength in midlife Zimbabwean women and association between pQCT outcomes and fracture *abs# 47*
- 3:42 PM **Aaron Schindeler**
Reversing high bone porosity in NF1 bone using dietary supplements *abs# 48*
- 3:54 PM **Nick Tran**
Assessing the robustness of evidence for the efficacy of anti-fracture medications *abs# 49*
- 4:06 PM **Shinsei Yambe**
Sclerostin, a marker for mature fibrochondrocytes, modulates the stiffness gradient to maintain tissue integrity of the fibrocartilaginous enthesis. *abs# 50*
- 4:18 PM **Thach Tran**
“Skeletal Age” for mapping the impact of fracture on mortality using clinical data *abs# 51*

Afternoon Tea

4:30PM - 5:00PM Concert Hall Floor

ANZBMS ECI B.O.N.E Symposium

5:00PM - 5:30PM Concert Hall Auditorium
Chairs: Kathryn Stok & Kara Anderson

5:00 PM **Michaela Tencerova**
Bone marrow adipose tissue under control of nutrient sensors *abs# 52*

ANZBMS AGM

5:30PM - 6:30PM Concert Hall Auditorium

Conference Dinner

7:00PM - 11:30PM Noah's on the Beach

Buses will transport people to the venue and will depart the Newcastle City Hall at 7:00pm and will be available to pick up guests from Noah's back to the Newcastle City Hall at 9:30pm, 10:30pm and 11:30pm.

Supported by  KYOWA KIRIN

WEDNESDAY 25TH OCTOBER 2023

Registration Open

8:30AM - 4:00PM

Concert Hall Floor

ANZBMS ECI B.O.N.E Symposium

9:00AM - 9:30AM

Chairs: Rachel Davey & Marc Sim

Concert Hall Auditorium

9:00 AM

Lama Alabdulaaly

Pth1r Signalling in Adipoq+ Bone Marrow Cells (MALPs) Decreases Bone Mass and Restricts the Anabolic Response to PTH *abs# 53*

ANZBMS Selected Orals

9:30AM - 10:30AM

Chairs: Rachel Davey & Marc Sim

Concert Hall Auditorium

9:30 AM

Nayan D Bhattacharyya

Minimally invasive longitudinal intravital imaging of cellular dynamics in intact long bone *abs# 54*

9:42 AM

Roger Zebaze

Bone Disorganization: A Novel Biomarker Unrelated to Bone Density and Structure that May Hold the Key to The Diagnosis of Atypical, Stress Fractures, and Other Unexplained Bone Diseases. *abs# 55*

9:54 AM

Dzenita Muratovic

Histological changes to the osteocyte peri-lacunocanalicular bone matrix that distinguish aseptic loosening from periprosthetic joint infection *abs# 56*

10:06 AM

Anoohya Gandham

Sarcopenia definitions and their association with non fracture injurious falls in older Swedish women from the SUPERB study *abs# 57*

10:18 AM

Han Liu

Revealing bone remodelling dynamics with longitudinal imaging *abs# 100*

Morning Tea

10:30AM - 11:00AM

Concert Hall Floor

Interface between patient, policy and advocacy Symposium

11:00AM - 12:00PM

Concert Hall Auditorium

Chairs: David Scott & Cassandra Smith

11:00 AM

Greg Lyubomirsky

Consumer Engagement for Better Outcomes *abs# 59*

11:15 AM

Solange SB Bernado

Fracture Care and Prevention Program - Enhancing Clinical Care *abs# 60*

11:30 AM

Consumer Advocate

A Consumer Perspective *abs# 61*

ANZBMS Debate - Animal models are an accurate model of human disease

Chair: Craig Munns

12:00PM - 1:00PM

Concert Hall Auditorium

FOR: Natalie Sims & Roderick Clifton-Bligh

AGAINST: Jill Cornish & Nathan Pavlos

Lunch

1:00PM - 2:00PM

Concert Hall Floor

Past Awardees Session

2:00PM - 2:45PM

Concert Hall Auditorium

Chairs: Jason Talevski & Natalie Sims

2:00 PM

David Scott

A digital voice assistant-supported exercise, nutrition and medication self-management program for older women with osteoporosis *abs# 62*

2:15 PM

Natalie K Hyde

Early life predictors of bone health *abs# 64*

2:30 PM

Kai Chen

Mapping chemistry and metabolism across the musculoskeletal system at the nanoscale *abs# 65*

ANZBMS Selected Orals

2:45PM - 3:45PM

Concert Hall Auditorium

Chairs: Jason Talevski & Natalie Sims

2:45 PM

Dana Bliuc

Measures of physical function are associated with increased fracture and mortality risk *abs# 66*

2:57 PM

Kara Anderson

Associations between ultra-distal forearm bone mineral density and incident fracture in women *abs# 67*

3:09 PM

Alexandra K O'Donohue

What a knock-out! Recombinant adeno-associated viruses for generation of post-natal bone knockouts *abs# 68*

3:21 PM

Belinda R Beck

Strengthening Bone with Evidence-Based Exercise Therapy in the Real World: 3D Hip Data from The Bone Clinic *abs# 69*

3:33 PM

Chaofeng Wang

Mechanism of mitochondrial pyruvate carrier inhibitor MSDC-0160 in preventing type 2 diabetic osteoporosis by reducing ROS production through regulating the tricarboxylic acid cycle *abs# 70*

Conference Close

3:45PM - 4:00PM

Concert Hall Auditorium

ANZBMS President Mark Forwood

#1

Actonel® EC

risedronate sodium (enteric - coated)

THE

PRESCRIBED ORAL BISPHOSPHONATE[#]

[#]Data on file. Actonel EC demonstrates the largest unit share of Australian oral bisphosphonate prescriptions¹

Early and sustained protection

Actonel® EC is proven to significantly improve BMD in early postmenopausal women from as early as 3 months^{2-5,7}

2-fold greater bioavailability⁺

The addition of EDTA means bioavailability with Actonel® EC taken with food is 2-FOLD greater than IR risedronate⁺⁷

⁺2-fold greater bioavailability for Actonel® EC 35mg Once-a-Week, taken 5 minutes after a high-fat breakfast, vs film-coated risedronate 35mg taken as recommended, 30 minutes before a meal (p-value not stated). Bioavailability measured as risedronate urinary excretion over 72 hours. ⁷Efficacy and safety data cannot be inferred from PK/PD data.⁷

NEW DATA!

Real-world fracture superiority

Actonel® EC reduced any fracture site by 37% vs. IR risedronate and 27% vs. alendronate^{Q,8}

^QReal world retrospective study on Women aged ≥ 60 yr with ≥ 2 oral bisphosphonate (OBPs) prescription fills with osteoporosis diagnosis and/or history of fracture were selected from a claims database (2009-2019). The index date and study cohorts (EC Ris, IR Risedronate, Alendronate) were based on the first observed OBPs dispensing. All eligible women on EC Ris were analyzed (N = 1,080). Comparator cohorts, randomly selected from women initiated on IR Ris and Ale to match the index year of women on EC Ris. Adjusted incidence rate ratios (IRR) were used to compare fracture risk between EC Ris and IR Ris/Ale; and in women with high fracture risk. Adapted from Eisman JA et al 2023⁸

Treatment flexibility

Actonel® EC allows for a pause of treatment while still maintaining fracture protection^{6,9}

PRESCRIPTION ONLY MEDICINE
KEEP OUT OF REACH OF CHILDREN

Actonel® EC *Once-a-Week* **35mg**
risedronate sodium

AUST R 166838
4 enteric-coated tablets



Theramex



Brand substitution not allowed



Include / print brand name on script

PBS Information: Actonel EC. Restricted Benefit for osteoporosis, established osteoporosis and corticosteroid-induced osteoporosis.

Please review the Product Information before prescribing. Full Production Information is available from Medical Information: 1800 THERAMEX (1800 843 726) or online at <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2019-PI-01321-1&d=201905161016933> OR by scanning the QR code

ACTONEL® EC 35MG WEEKLY MINIMAL PRODUCT INFORMATION. INDICATIONS: Treatment of: 1) osteoporosis, 2) glucocorticoid-induced osteoporosis, 3) preservation of bone mineral density in patients on long term corticosteroid therapy. **CONTRAINDICATIONS:** Risedronate: Hypersensitivity to the drug or ingredients, hypocalcaemia, inability to stand or sit upright for at least 30 minutes. **PRECAUTIONS:** Risedronate: Hypocalcaemia; bone and mineral metabolism dysfunction; calcium and vitamin D if dietary intake is inadequate; severe renal impairment; oesophageal reaction, inflammatory bowel disease; osteonecrosis of the jaw; osteonecrosis of the external auditory canal; dental examination with preventive dentistry; avoid invasive dental procedures; atypical stress fractures; pregnancy (Category B3); certain medications (e.g. calcium supplements, antacids) should not be taken with Actonel EC; patients with a history of oesophagitis, gastritis, oesophageal ulcerations and gastroduodenal ulcerations. **INTERACTIONS:** Risedronate does not induce or inhibit CYP450 enzymes. **ADVERSE EVENTS:** Risedronate: Very Common: nasopharyngitis. Common: abdominal and musculoskeletal pain, influenza, urinary tract infection, bronchitis, diarrhoea, constipation, vomiting, nausea, arthralgia, back pain, hypertension, hypercholesterolaemia. **DOSAGE AND ADMINISTRATION:** Tablet need to be swallowed as a whole with a full glass of plain water in an upright position and patient need to stay upright for 30 more minutes. See full PI for full information. **STORAGE:** store below 25 °C. Based on the PI last updated April 2021. Abbreviations: EC: enteric-coated; IR: immediate-release; GI: Gastric Irritation; IRR = incidence rate ratios

Abbreviations: EC: enteric-coated; BMD: bone mineral density; EDTA: ethylenediaminetetraacetic acid; IR: immediate-release; CI = confidence interval; Ale: alendronate; IRRs: incidence rate ratios; OBPs: oral bisphosphonates. **References:** 1. MIDAS data on file Q2 2022. Actonel EC has a 37% unit share of total Australian oral bisphosphonate prescriptions 2. Bala Y, et al. J Bone Miner Res. 2014 3. Ignac Fogelman, et al. The Journal of Clinical Endocrinology & Metabolism. 2000 4. Hooper MJ et al. Climacteric. 2005 5. Thomasius F et al Osteoporosis International, (2022) 33:217–228 6. McClung. Bisphosphonates: Optimising osteoporosis protection. Best practice from the 2018 National Osteoporosis Foundation of South Africa (NOFSA) Congress 7. Actonel® EC Approved Product Information, April 2021 8. Eisman JA et al. Osteoporos Int. 2023 May;34(5):977-991 9. Watts NB et al Osteoporosis Int (2008) 19:365–372 Sponsored in Australia by Theramex Australia Pty Ltd, ABN 37 623 186 845, 60 Margaret Street, Sydney, NSW 2000. www.theramex.com.au. Date of preparation: September 2023. 011380.

Theramex
For Women, For Health



POSTER LISTING

PLENARY POSTERS (CONCERT HALL FLOOR)

Abdullrahman M. Al-Bishari

Osseointegration and anti-infection of dental implant under osteoporotic conditions promoted by Gallium oxide nano-layer coated titanium dioxide nanotube arrays *abs# 101*

Tetsuya Yoshimoto

Inflamed osteocytes directly induce inflammatory osteolysis through MYD88 signalling in bacterial bone infection. *abs# 102*

Lay Thant

Chemical digestion-assisted extracellular matrix profiling of differentiating osteoblasts *abs# 103*

Nathalie Bock

Development of *in vitro* 3D osteocyte culture models in ECM-derived hydrogels *abs# 104*

Kara Anderson

Associations between bone material strength index and FRAX scores *abs# 105*

Grahame J Elder

Fracture following kidney and simultaneous pancreas-kidney transplantation is predicted by DXA-derived bone mineral density and advanced hip analysis *abs# 106*

Khalid B Almutairi

Global prevalence of osteoporosis in rheumatoid arthritis: Systematic review and meta-analysis *abs# 107*

Bridie S Mulholland

Osteoporosis Development in Patients with Acute Kidney Injury *abs# 108*

Shanal Kumar

Fracture prevalence in adults with cystic fibrosis with end-stage lung disease post transplantation *abs# 109*

Narelle E McGregor

Isolation and comparison of osteoblast lineage cells from periosteal, endocortical and intracortical bone surfaces *abs# 110*

POSTER TOUR 1 - TOP 5 CLINICAL & BASIC SCIENCE POSTERS (CUMMINGS ROOM)

Liuyuan Chen

Roquin1 maintains bone mass by repressing mitochondrial biogenesis in osteoclasts *abs# 200*

Itamar Levinger

High-intensity interval training mildly improves trabecular bone microarchitecture in adult male C57BL/6 mice *abs# 201*

Hikaru Ms. Otsuka

Age-related normative values of bone microarchitecture parameters in older Japanese: the Bunkyo Health Study. *abs# 202*

Jonathan Phuong

Development and evaluation of an osteoporosis medication adherence intervention *abs# 203*

Charles Inderjeeth

Fracture falls frailty and sarcopenia predict hospitalisation risk in geriatric populations referred for ACAT assessment *abs# 205*

Shae E Quirk

Quality of life in population-based women with comorbid arthritis and mood disorders *abs# 206*

Belayneh Mengist Miteku

Association between lower gait speed or handgrip strength and their combination with depressive symptoms in community-dwelling older adults *abs# 207*

Felicity Stringer

Commencement of osteoporosis therapy in patients presenting with neck of femur fracture at University Hospital Geelong *abs# 208*

Belinda R Beck

Improving Bone, Function, Falls and Fractures with Evidence-Based Exercise Therapy for Osteoporosis in the Real World *abs# 209*

ANZBMS POSTER VIEWING - ODD NUMBERS (CUMMINGS ROOM)**Agnieszka Arthur**

Investigating Eph-ephrin communication within the neuro-osteo network utilising the avian embryo *abs# 211*

Qian - Huang

Sema3f regulates bone homeostasis *abs# 213*

Abdullrahman M. Al-Bishari

JK-2 loaded electrospun membrane for promoting bone regeneration *abs# 215*

Jonathan Phuong

Bone health education in Australian PDHPE classrooms *abs# 217*

Takka Sun

Association of frailty (J-CHS standard) with related factors among older adults living at home in Tokyo; A cross-sectional study *abs# 219*

Carlie Bauer

The effect of prednisolone on lipocalin-2 and its forms in young males effects of exercise *abs# 221*

Ali Ghasem-Zadeh

Bone Fragility is the Result of Bone Loss from Frugally Assembled Larger Bones *abs# 225*

Soichiro Kimura

Three cases of vitamin D deficient osteomalacia probably associated with mild dysfunctional variants in the causative genes for vitamin D-dependent rickets *abs# 227*

Shanal Kumar

Change in Z-score in young adults with Cystic Fibrosis on modulator therapies attending a large CF Centre. *abs# 231*

Bridie S Mulholland

Prevalence of dementia in patients with chronic kidney disease and osteoporosis: a retrospective cohort analysis *abs# 233*

Tuan V Nguyen

"Skeletal Age" for quantifying the association between bone mineral density and mortality *abs# 235*

Cassandra Smith

Osteoporosis is associated with increased risk for cardiovascular disease mortality in community dwelling older women: the Perth Longitudinal Study of Ageing in Women *abs# 237*

Jason Talevski

Integrating Post-Fracture Care into the Primary Care Setting (interFRACT): Phase 1 Results of a Mixed-Methods Co-Design Study *abs# 239*

Kara Anderson

Bipolar disorder and markers of bone turnover: a case control study *abs# 241*

Xi May Zhen

Osteoporosis in Eating Disorders: A Clinical Update *abs# 243*

Pierre-Nicolas Boyer

FEVR and fractures: *CTNFB1* mutation as a cause of autosomal dominant osteoporosis-pseudoglioma-like syndrome *abs# 247*

Dave Duggan

Bone tumours with giant cell proliferation on histology in primary hyperparathyroidism: Are they always brown tumours? *abs# 249*

Jeremy Knott

Severe osteoporosis in a female with type 1 diabetes and pancreatic exocrinopathy with chronic malabsorption and vitamin D deficiency: case report *abs# 251*

Saleen SN Nottingham

Rare cause of osteoporosis secondary to systemic mastocytosis *abs# 253*

Isabelle Smith

Atypical femur fracture... What to do AFTER Teriparatide? *abs# 255*

Alexander X Yao

A Case Report of SH3BP2-Related Autosomal Dominant Cherubism in an Adult Treated with Denosumab *abs# 257*

POSTER TOUR 2 - CHRISTOPHER AND MARGIE NORDIN YOUNG INVESTIGATOR AWARD POSTERS (CUMMINGS ROOM)**Jonathan Phuong**

An implementation science approach to community pharmacy osteoporosis screening *abs# 28*

Krisel De Dios

Rate of bone loss is associated with fracture risk: The Study of Osteoporotic Fractures *abs# 29*

Micaela Quinn

Skeletal effects of neratinib treatment and *Blautia luti* supplementation in tibial trabecular bone of albino Wistar rats *abs# 30*

Mike Lin

Severe Low Bone Mineral Density is Common in Patients with Beta Thalassaemia Major: A Single Centre Experience *abs# 31*

Pholpat Durongbhan

Quantification of abnormal cortical bone surface remodelling in preclinical models of arthritis *abs# 32*

Khuong-Duy Hoang

Association between knee osteoarthritis and volumetric bone mineral density *abs# 33*

Mia Percival

Gestational vitamin D and offspring fracture risk: Do associations persist into mid adolescence? *abs# 34*

Behnaz Azimi Manavi

Antipsychotic medication use and fracture: a case-control study *abs# 35*

Ngoc Huynh

Estimating “Skeletal Age” by Bone Loss in Elderly Men and Women *abs# 36*

Lucy Collins

Does long-term antiresorptive administration lead to atypical fractures at other skeletal sites excluded from the ASBMR atypical femur fracture (AFF) case definition? A systematic review *abs# 37*

ANZBMS POSTER VIEWING - EVEN NUMBERS (CUMMINGS ROOM)

Dina Abdelmoneim

In vitro and *in vivo* investigation of antibacterial bone regenerative scaffolds *abs# 210*

Julian FH Chu

Generating cell-based models of FGFR3-related diseases *abs# 212*

Abdullrahman M. Al-Bishari

Innovative Approach to Guided Bone Regeneration with Triple-Drug Sustained Release for Advanced Bone Regeneration *abs# 214*

Michelle Maugham-Macan

Investigating early-onset osteoporosis in individuals with Down syndrome *abs# 216*

Jemima E. Schadow

A systematic review of parameters used for the assessment of subchondral bone in osteoarthritis (OA) with computed tomography (CT) *abs# 218*

Kara B Anderson

Bone mineral density and sedentary ageing: a cross-sectional analysis *abs# 220*

Julie Briody

Cortical bone mineralization density distribution in paediatrics – can peripheral QCT images act as a pain-free bone biopsy? *abs# 222*

Lucy Collins

Quality of life (QoL) and transition care for patients with Osteogenesis imperfecta (OI) and X-linked hypophosphataemia (XLH) *abs# 224*

Yinghong Zhou

Immunoengineering for periodontal tissue regeneration *abs# 226*

Jeremy Knott

Severe osteoporosis in a female with type 1 diabetes and pancreatic exocrinopathy with chronic malabsorption and vitamin D deficiency. *abs# 228*

Shanal Kumar

Incidence and prevalence of osteoporotic fracture in adult lung transplant recipients: a single centre audit *abs# 230*

Itamar Levinger

Prevalence of diagnosable depression in patients awaiting orthopaedic specialist consultation: a cross-sectional analysis *abs# 232*

Dinh-Tan Nguyen

BONEcheck: a digital tool for personalized bone health assessment *abs# 234*

Alexander J. Rodriguez

Coronary artery calcification is associated with smaller increases in femoral neck bone mineral density in patients on anti-resorptive therapy *abs# 236*

Jason Talevski

Associations Between Social Disadvantage and Bone, Muscle, and Physical Function Outcomes in Community-Dwelling Older Adults: The SEBA Study *abs# 238*

Emma West

Associations between sarcopenia and domains of quality of life in older adults *abs# 240*

Ayse Zengin

A qualitative assessment of healthcare professionals bone health knowledge and management of people with multiple sclerosis *abs# 242*

Sharjeel SA Ahmad

MET-Call during Zoledronate Infusion: An Unusual Case of Allergy *abs# 244*

Tomasz J Block

Broken bones, miserable moans, and unfortunate unknowns *abs# 246*

Liam Clifford

Severe hypocalcaemia postoperatively from a laryngectomy, total thyroidectomy and total parathyroidectomy requiring Teriparatide *abs# 248*

Tavleen Kaur

Management of osteoporosis and fracture risk in a 30-year-old 6 months post-partum woman with adult-onset hypophosphatasia (HPP) *abs# 250*

Cat Shore-Lorenti

Bone microarchitecture and disorganized bone tissue in a young woman with pycnodysostosis and an atypical femur fracture: A case report *abs# 254*

Felicity Stringer


Fragile Foundations: A Genetic Cause of Osteoporosis *abs# 256*

Sylvia Ye

Concurrent denosumab and parenteral iron therapy precipitating severe hypocalcaemia and hypophosphataemia: a case report *abs# 258*

SPONSOR AND TRADE PARTICIPANTS

EXHIBITION FLOOR PLAN – CONCERT HALL FLOOR



GOLD & COFFEE CART SPONSOR

Kyowa Kirin

www.kyowa-kirin.com

Kyowa Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies. We strive to understand the unmet needs of patients with rare diseases to bring a profound and positive impact to their journey. Kyowa Kirin Australia is focussed on delivering a unique pipeline of medicines to Australian patients with unmet rare disease needs. Currently, our main area of focus is X-linked hypophosphataemia (XLH), a rare, genetic, and progressive disease. You can learn more about the business at www.kyowakirin.com/australia.

Booth 1

GOLD SPONSOR

Amgen Australia

www.amgen.com.au

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief – and the core of our strategy – is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Booth 2

DESTINATION SPONSOR

Destination NSW

www.destinationnsw.com.au

Destination NSW acknowledges and respects Aboriginal people as the state's first people and nations and recognises Aboriginal people as the Traditional Owners and occupants of New South Wales land and water. Welcome to New South Wales – a place to feel free, feel alive, feel new. As the official tourism, destinations and events website, let us inspire your next travel tale. Follow rainforest birdsong to thundering waterfalls. Glide down glittering snowfields or slip into the silken sea on a white-sand beach. Taste world-class wines, ocean-fresh oysters, juicy cherries and fragrant truffles on meandering road trips. Connect with outback stories, making new friends along the way. So, where to first?

SYMPOSIUM SPONSOR

Alexion

Booth 8

www.alexion.com

Alexion, Astra Zeneca Rare Diseases, has been a leader in rare diseases for 30 years. Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. We work alongside healthcare providers, patient advocacy organisations and governments to best serve patients by innovating and expanding our knowledge of rare diseases. Our goal is to bring hope to patients and families by delivering scientific advances.

EXHIBITORS

Australia and New Zealand Bone and Mineral Society (ANZBMS)

Booth 6

www.anzbms.org.au

ANZBMS is a professional medical / scientific society established in 1988 to bring together clinical and experimental scientists and physicians actively involved in the study of bone and mineral metabolism in Australia and New Zealand. The mission of the ANZBMS is to be the premier Australasian society in the field of bone and mineral metabolism through promoting excellence in bone and mineral research, fostering the integration of clinical and basic science, and facilitating the translation of our science to health care and clinical practice. Key objectives to achieve these goals include the nurturing and development of the future generations of basic and clinical scientists, and the dissemination of new knowledge in bone and mineral metabolism through our Annual Scientific Meeting. The ANZBMS will be proactive in shaping research and health policies based on scientific advances in our field.

Bone Health

Booth 6

www.bonehealth.org.au

The Bone Health Foundation is a not for profit organisation that raises money for education and research into bone health and musculoskeletal conditions that affect Australian's of all ages.

City of Newcastle

Booth 9

www.visitnewcastle.com.au/visitor-information/visitor-information-centre

Drop by the Newcastle Visitor Information Centre to experience the best the city has to offer. The welcoming staff will share all their insider tips for exploring the city and uncovering it's hidden gems. It also stocks a range of maps and brochures on local attractions as well as a wide range of products made by Newcastle makers and traders. Drop by for a keep sake and a warm welcome to Newcastle!

Gedeon Richter

Booth 5

www.gedeonrichter.com.au

Established in Sydney in October 2017, through the acquisition of Finox Biotech, Gedeon Richter Australia has a growing product range in Women's Health and Osteoporosis. The company boasts a 120-year history with founder pharmacist Gedeon Richter manufacturing the first drugs in his laboratory in 1901.

Getz Healthcare

Booth 7

www.getzhealthcare.com

Getz Healthcare has represented the Lunar brand for over thirty years. Partnering with the manufacturer, GE Healthcare, Getz offers advanced DEXA solutions including Prodigy and iDXA for use in clinical and research applications. To support our customers we provide comprehensive sales, applications and technical support across Australia and New Zealand.

Theramex

Booth 4

www.theramex.com.au

Theramex Australia is a specialty pharmaceutical company solely committed to supporting the health needs of women. By working closely with our partners and healthcare professionals, Theramex Australia provides a diverse portfolio of treatments that help women through life's stages.

ATTENDEES

Dina Abdelmoneim University of Otago, New Zealand	Fiona Britten Royal Brisbane and Women's Hospital, QLD	Jean Doyle RNSH, NSW
Sharjeel Ahmad Austin Health, VIC	Laura Calvi University of Rochester, United States	Dave Duggan Waikato Hospital New Zealand, New Zealand
Lama Alabdulaaly Harvard University, United States	Lore Carelse Gedeon Richter, NSW	Pholpat Durongbhan The University of Melbourne, VIC
Jasna Aleksova Monash Health, VIC	Jacqueline Center Garvan Institute of Medical Research and St Vincent's Hospital, NSW	Anthony Earp Kyowa Kirin, NSW
Khalid Almutairi The University of Western Australia, WA	Ryan Chai Garvan Institute of Medical Research, NSW	Peter Ebeling Monash University, VIC
Kara Anderson Deakin University, VIC	Irene Chan Vic, VIC	Grahame Elder Westmead Hospital, NSW
Agnieszka Arthur University of Adelaide, SA	Kai Chen The University of Western Australia, WA	Tania Ellul School of Biomedicine, The University of Adelaide, SA
Claudia Ashkar St Vincent's Hospital Melbourne, VIC	Liuyuan Chen guangxi medical university, China	Mary Louise Fac St. Vincent's Institute of Medical Research, VIC
Christal Au-Yeung Westmead Institute for Medical Research, Kids Research, NSW	Jerry Chng Kyowa Kirin Australia Pty Ltd, NSW	Jim Fawcett ASN Events, VIC
Behnaz Azimi Manavi Deakin University, VIC	Julian Chu The University of Sydney, NSW	David Findlay University of Adelaide, SA
Sobana Balakrishnan Capital, Coast and Hutt Valley-Wellington Hospital, New Zealand	Liam Clifford Gosford District Hospital, NSW	Kaitlyn Flynn The University of Queensland, QLD
Tiffany Bamford Kyowa Kirin Australia, NSW	Lucy Collins Royal Children's Hospital, VIC	Mark Forwood Griffith University, QLD
Carlie Bauer Victoria University, VIC	Joanna Cook Bone Health Foundation, SA	Prageeth Gamage Monash University, VIC
Belinda Beck Griffith University, QLD	Mark Cooper University of Sydney, NSW	Kirtan Ganda Concord Repatriation General Hospital, NSW
Solange Bernado Sunshine Hospital, VIC	Jillian Cornish University of Auckland, New Zealand	Anoohya Gandham Australian Catholic University, VIC
Nayan Bhattacharyya Garvan Institute, NSW	Tania Crotti University of Adelaide, SA	Abadi Kahu Gebre Edith Cowan University, WA
Dana Bliuc Garvan Institute of Medical Research, NSW	Melita Daru Healthy Bones Australia, NSW	Chris George Amgen, NSW
Tomasz Block Royal Hobart Hospital, TAS	Rachel Davey University of Melbourne, Austin Health, VIC	Natalie Giles Rheumatology sa, SA
Nathalie Bock Queensland University of Technology, QLD	Simon Dawson Kyowa Kirin Australia, NSW	Jade Giorgio Amgen, NSW
Yolande Boucher Theramex, ACT	Krisel De Dios University of Technology Sydney, NSW	Christian Girgis Westmead Hospital, Sydney, NSW
Tiree Bowden Gedeon Richter Australia, NSW	Sarah Dixon Sunshine Coast University Hospital, QLD	Katherine Griffin Gold Coast University Hospital, QLD
Pierre-Nicolas Boyer Royal Brisbane and Women's Hospital, QLD	Alan Doube Te Whatu Ora Waikato, New Zealand	Evelyn Hao Blacktown Hospital, NSW
Julie Briody The Children's Hospital at Westmead, NSW	Melissa Douglas Australian and New Zealand Bone and Mineral Society, NSW	Jeffrey Hassall Amgen Australia, NSW

Jinwen He Townsville Hospital, QLD	Jiao Jiao Li University of Technology Sydney, NSW	Tuan Nguyen University of Technology Sydney, NSW
Khuong-Duy Hoang University of Technology Sydney, NSW	Mike Lin Royal Prince Alfred Hospital, NSW	Saleen Nottingham Waikato hospital, New Zealand
Qian Huang Guangxi Medical University, China	Han Liu University of Melbourne, VIC	Micheál Ó Breasail School of Clinical Sciences, Faculty of Medicine, Monash Medical Centre, Nursing and Health Sciences, Monash University, VIC
Ngoc Huynh University of Technology Sydney, NSW	Matthew Luttrell Wollongong Hospital, NSW	Alexandra O'Donohue Kids Research, Children's Hospital at Westmead, NSW
Natalie Hyde Deakin University, VIC	Judy Luu John Hunter Hospital, NSW	Hikaru Otsuka Juntendo University, Japan
Charles Inderjeeth North Metropolitan Health & University of Western Australia, WA	Greg Lyubomirsky Healthy Bones Australia, NSW	Yeung-Ae Park Royal Melbourne Hospital, VIC
Sandra Iuliano University of Melbourne / Austin Health, VIC	Eugenie Macfarlane ANZAC Research Institute, University of Sydney, NSW	Benjamin Parker University of Melbourne, VIC
Amanda Ji Cairns Hospital, QLD	Luciano Martelotto Adelaide Centre for Epigenetics SAIGENCI University of Adelaide, SA	Nathan Pavlos University of Western Australia, WA
Ivone Johnson Australian and New Zealand Bone and Mineral Society, NSW	T. Jack Martin St Vincent's Institute of Medical Research, VIC	Felix Pena Getz Healthcare, NSW
Tavleen Kaur RACP, NSW	Rebecca S Mason University of Sydney, NSW	Mia Percival Deakin University, VIC
Jessica Kelly CDHB, New Zealand	Michelle Maugham-Macan University of the Sunshine Coast, QLD	Allison Pettit Mater Research Institute, University of Queensland, QLD
John Kemp University of Queensland, QLD	Michelle McDonald The University of Sydney, ACT	Annalise Philcox Calvary Mater Hospital Newcastle, NSW
David (Dong Wook) Kim Dr David Kim Limited, New Zealand	Jo McGovern Theramex Australia, NSW	Jonathan Phuong University of Sydney, NSW
Soichiro Kimura The University of Tokyo, Japan	Narelle McGregor Bone Cell Biology and Disease Unit, St Vincent's Institute of Medical Research, VIC	Nicholas Pocock St Vincent's Hospital, NSW
Francelle Knight Kyowa Kirin Australia, NSW	Jakub Mesinovic Deakin University, VIC	Micaela Quinn The University of Adelaide, SA
Jeremy Knott St George Hospital, NSW	Belayneh Miteku Deakin University, VIC	Ian Reid University of Auckland, New Zealand
Natalie Koh St. Vincent's Institute of Medical Research, VIC	Gabi Mittas Amgen Australia, NSW	Yumie Rhee Yonsei University College of Medicine, South Korea
Shanal Kumar Queensland Health, QLD	Bridie Mulholland University of Wollongong, NSW	Ann Robinson Gold Coast University Hospital, QLD
Shejil Kumar Royal North Shore Hospital, NSW	Benjamin Mullin University of Western Australia, WA	Alexander Rodriguez Monash University, VIC
Susan Kurrle University Of Sydney, NSW	Craig Munns Queensland Children's Hospital, QLD	Michael Rogers Garvan Institute of Medical Research, NSW
Syndia Lazarus Royal Brisbane and Women's Hospital, QLD	Dzenita Muratovic University of Adelaide, SA	Christopher Rowe John Hunter Hospital, NSW
Nicola Leaney Theramex, NSW	Ben Nash Austin Health, VIC	Christine Rowland Greenslopes Private Hospital, QLD
Itamar Levinger Victoria University, VIC	Dinh-Tan Nguyen University of Technology Sydney, NSW	Toufic Safi University of Wollongong, NSW
Joshua Lewis Edith Cowan University, WA	Huy Nguyen University of Technology Sydney, NSW	

Jemima Schadow
University of Melbourne, VIC

Aaron Schindeler
The Children's Hospital at Westmead, NSW

David Scott
Deakin University, VIC

Jas-mine Seah
Austin Health, VIC

Markus Seibel
University of Sydney, NSW

Atit Shah
ASN Events, VIC

Julia Shrosbree
Beaches Endocrinology, NSW

Marc Sim
Edith Cowan University, WA

Peter J Simm
Royal Children's Hospital Melbourne, VIC

Natalie Sims
St Vincent's Institute, VIC

Sunny Singh
Gedeon Richter, NSW

Cassandra Smith
Edith Cowan University, WA

Gary Smith
ASN Events, QLD

Isobelle Smith
Royal Prince Alfred Hospital, NSW

Dezhi Song
Guangxi Medical University, China

Felicity Stringer
St Vincent's Health, VIC

Takka Sun
Juntendo University, Japan

Abigail Swager
Auckland, Middlemore hospital, New Zealand

Jason Talevski
Northern Health, VIC

Michaela Tencerova
Institute of Physiology of the Czech Academy of Sciences, Czech Republic

Lay Thant
Niigata University, Japan

Aye Thin
Tamworth Hospital, NSW

Michael Thompson
Menzies Research Institute Tasmania, TAS

Jenny Tran
Amgen Australia, NSW

Nick Tran
Macquarie University, NSW

Thach Tran
Garvan Institute of Medical Research, NSW

Mike Turner
Hologic, NSW

Lisa Van
Gedeon Richter, NSW

Liesbeth Vandenput
Australian Catholic University, VIC

Joel Vanderniet
The Children's Hospital at Westmead, NSW

Rebecca Vass
Alexion Pharmaceuticals, NSW

Varun Venkatesh
University of Melbourne, VIC

Ursula Walker
Theramex, ACT

Talia Walter
Te Whatu Ora Health New Zealand, New Zealand

Chaofeng Wang
Guangxi Medical University, China

James Webb
Gedeon Richter Australia, NSW

Benjamin Weeks
Griffith University, QLD

Kavindi Weerasinghe
Deakin University, VIC

Sally Wills
ASN Events, VIC

Peter Wong
Western Sydney Local Health District, NSW

Dania Yaghobian
Alexion, NSW

Shinsei Yambe
Department of Molecular Biology and Biochemistry, Graduate School of Biomedical & Health Sciences, Japan

Alexander Yao
Royal Melbourne Hospital / Albury Wodonga Health, VIC

Sylvia Ye
Western Health, VIC

Rui Qian Yeu
Auckland City Hospital, New Zealand

Sheng Yin
Central South University, SA

Tetsuya Yoshimoto
Hiroshima University Hospital, Japan

Margaret Zacharin
royal children's Hospital, VIC

Anis Zand Irani
Gympie Hospital, QLD

Roger Zebaze
Monash University, School of Clinical Sciences, VIC

Ayse Zengin
Monash University, VIC

Jane Zhang
Wollongong Hospital, NSW

Yuandan Zhang
Mater Research Institute UQ, QLD

Xi May Zhen
Blacktown Hospital, NSW

Hong Zhou
ANZAC Research Institute, NSW

Yinghong Zhou
University of Queensland, QLD

Jasmine Zhu
University of Melbourne, VIC

Rachael Zuzek
Wollongong Hospital, NSW

NOTES

NOTES



Terrosa

teriparatide

Let's build together



TERROSA®: An anabolic treatment for your osteoporosis patients¹

- Now the only teriparatide available on the PBS²
- Substitutable biosimilar of FORTEO® for all approved indications¹⁻³
- Promotes bone formation^{1,4,5}

Teriparatide body of evidence

- Demonstrated effectiveness across all indicated patient groups in real-world studies spanning the United States, Europe and South-East Asia⁶
- >20 years of worldwide teriparatide experience^{7,8} with a well-established safety profile^{1,6,9}
- Anabolics are recommended as a first-line osteoporosis treatment for all TERROSA® approved indications and patient groups^{*10-14}



Find resources for you and your patients at www.myterrosa.com or scan the QR code

Password for HCPs: Terrosa02
Password for patients: Terrosa01

*TERROSA® is PBS-reimbursed for the treatment of severe established osteoporosis and the patient must have experienced ≥1 symptomatic new fracture after ≥12 months continuous therapy with an anti-resorptive agent at adequate doses.² Refer to the PBS Schedule for Full Authority Required information. TERROSA® is indicated for the treatment of:¹ • Osteoporosis in postmenopausal women • Primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures • Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture

Please review the full Product Information (PI) before prescribing. Full Product Information is available by scanning the QR code OR on request from Gedeon Richter Australia Medical Information on 1300 GEDEON (1300 433 366).



PBS Information: Authority Required. For use in patients that meet the treatment & clinical criteria for initial or continual treatment of severe established osteoporosis. Treatment must not exceed a lifetime maximum of 18 months therapy. Refer to PBS Schedule for Full Authority Required information. This product is not listed on the PBS for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy at high risk of fracture.

References 1. TERROSA® Approved Product Information. August 2022. 2. Australian Government Department of Health. Pharmaceutical Benefits Scheme. Teriparatide. www.pbs.gov.au/medicine/item/12670W. Accessed Aug 2023. 3. Australian Government Department of Health. Pharmaceutical Benefits Scheme Biosimilar Teriparatide. www.health.gov.au/resources/publications/biosimilar-medicine-fact-sheet-teriparatide. Accessed Aug 2023. 4. Osagie-Clouard L *et al.* *Bone Joint Res* 2017;6:14-21. 5. Raterman HG *et al.* *Drugs* 2019;79:1065-87. 6. Hauser B *et al.* *J Clin Med* 2021;10:1403. 7. Blick SKA *et al.* *Drugs* 2008;68(18):2709-37. 8. Forteo® Approved Product Information. May 2023. 9. Kendler DL *et al.* *Lancet* 2018;391:230-40. 10. Ebeling PR *et al.* Position Statement on the Management of Osteoporosis – Fifth Edition. 2023. Available at: <https://healthybonesaustralia.org.au/health-care-professionals/guidelines-statements>. Accessed Aug 2023. 11. LeBoff *et al.* *Osteoporos Int* 2022;33(10):2049-102. 12. Camacho P *et al.* *Endocr Pract* 2020;26(Suppl 1):1-46. 13. American College of Rheumatology. Glucocorticoid-Induced Osteoporosis Guideline. 2023. Available at: <https://rheumatology.org/glucocorticoid-induced-osteoporosis-guideline>. Accessed Aug 2023. 14. Dimar J *et al.* *Neurosurgery* 2021;89(Suppl 1):S19-S25. TERROSA® is a registered trademark of Gedeon Richter. FORTEO® is a registered trademark of Eli Lilly and Company. Gedeon Richter Australia Pty Ltd ABN 98 602 550 274. Suite 902/15 Blue St, North Sydney NSW 2060. Date of preparation: September 2023. COMS-0044-Sep-2023. GRTE30682W. Ward6.



GEDEON RICHTER

FEEL
LOST IN



THE
MOMENT

📍 Lord Howe Island



visitnsw.com

feel new south wales